论文部分内容阅读
为探讨~(186)铼(~(186)Re)用于放射免疫显像的价值,用抗人结肠癌单克隆抗体(MAb)SC3A和以抗坏血酸为还原剂的直接标记法,对SnCl_2还原的~(186)Re标记物在荷结肠癌裸鼠体内的生物学分布及放射免疫显像进行研究。结果显示,本法的标记率均达96%～99%,标记物较稳定。在体与250倍以上的二乙烯三胺五乙酸(DTPA)和人血清白蛋白在37℃共育24h。未见标记物~(186)Re-SC3A解离。用过量肿瘤细胞抗原结合法测定。标记物抗体活性达90%～96%。48h活性下降〈10%。在注射~(186)Re-SC3A后24～48h肿瘤显像清晰,尤以48h为佳。这为~(186)Re用于临床放射免疫诊断提供了有关数据,并为其用于放射免疫治疗奠定了基础。
To investigate the value of ~(186)铼(~(186)Re) for radioimmunoimaging, SnCl2 was reduced by direct labeling with anti-human colon cancer monoclonal antibody (MAb) SC3A and ascorbic acid as reducing agent. The biodistribution and radioimmunoimaging of ~(186)Re marker in colon cancer-bearing nude mice were studied. The results showed that the labeling rate of this method reached 96% to 99%, and the markers were relatively stable. In vivo with 250 times more diethylene triamine pentaacetic acid (DTPA) and human serum albumin co-cultured at 37 °C for 24 h. No marker ~ (186) Re-SC3A dissociated. Determined by the excess tumor cell antigen binding method. The marker antibody activity reached 90% to 96%. 48h activity decreased <10%. After 24 ~ 48 hours of injection of ~(186)Re-SC3A, the tumor imaging was clear, especially 48 hours. This provides ~(186)Re for clinical radioimmunoassay diagnosis and provides the basis for its use in radioimmunotherapy.